Merck’s Richard R. DeLuca sells 58,185 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Merck & Co., Inc. executive Richard R. DeLuca, executive vice president and president of Merck Animal Health, exercised options for 58,185 common shares on November 12, 2026, at an adjusted exercise price of $77.62 per share, then sold 58,185 shares at a weighted average of $148.0085 per share. The sale occurred in multiple transactions priced from $148.0000 to $148.0800. His reported option position after the transaction was zero; he reported 1,335.9494 shares indirectly through a 401(k).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3, F4 | 58,185 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 58,185 | $77.62 | $4.52M |
| Sale | Common Stock F2 | 58,185 | $148.0085 | $8.61M |
| Holding | Common Stock - 401(k) Plan F1 | -- | -- | -- |
Footnotes (4)
- F1. Holdings include shares acquired in dividend reinvestment transactions.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.0000 to $148.0800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F3. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- F4. The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
Key Figures
Key Terms
weighted average price financial
exercise price financial
exercisable financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When did Richard R. DeLuca’s MRK options vest and expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.